A
93.67
1.92 (2.09%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Axsome Therapeutics, Inc. | Bullish | Bullish |
Stockmoo Score
0.0
|
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Eventide Asset Management, Llc | 30 Jun 2024 | 938,714 |
| Alethea Capital Management, Llc | 30 Jun 2024 | 740,888 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 180.00 (HC Wainwright & Co., 92.16%) | Buy |
| Median | 130.50 (39.32%) | |
| Low | 95.00 (B of A Securities, 1.42%) | Hold |
| Average | 130.50 (39.32%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 89.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 09 Sep 2024 | 107.00 (14.23%) | Buy | 94.09 |
| 06 Sep 2024 | 107.00 (14.23%) | Buy | 93.19 | |
| HC Wainwright & Co. | 05 Sep 2024 | 180.00 (92.16%) | Buy | 93.69 |
| 22 Aug 2024 | 180.00 (92.16%) | Buy | 87.11 | |
| Needham | 05 Sep 2024 | 130.00 (38.79%) | Buy | 93.69 |
| 22 Jul 2024 | 130.00 (38.79%) | Buy | 86.05 | |
| Wells Fargo | 03 Sep 2024 | 140.00 (49.46%) | Buy | 89.65 |
| RBC Capital | 22 Jul 2024 | 131.00 (39.85%) | Buy | 86.05 |
| B of A Securities | 18 Jul 2024 | 95.00 (1.42%) | Hold | 82.14 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SAAD MARK E | - | 91.03 | -11,016 | -1,002,786 |
| Aggregate Net Quantity | -11,016 | |||
| Aggregate Net Value ($) | -1,002,786 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 91.03 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SAAD MARK E | Director | 11 Sep 2024 | Automatic sell (-) | 11,016 | 91.03 | 1,002,786 |
| SAAD MARK E | Director | 11 Sep 2024 | Option execute | 11,016 | - | - |
| Date | Type | Details |
|---|---|---|
| 04 Sep 2024 | Announcement | Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine |
| 27 Aug 2024 | Announcement | Axsome Therapeutics to Participate in Investor Conferences in September |
| 21 Aug 2024 | Announcement | Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc. |
| 05 Aug 2024 | Announcement | Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update |
| 11 Jul 2024 | Announcement | Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |